Estrogen replacement therapy and coronary artery disease

Current Opinion in Cardiology

Volumn 13, Issue 4, 1998, Pages 223-231

  Peterson, Linda R ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; LIPID;

ATHEROGENESIS; BLOOD CLOT LYSIS; CAUSE OF DEATH; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; ESTROGEN THERAPY; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPID OXIDATION; MENOPAUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY PREVENTION; THROMBOSIS; TRANSDERMAL DRUG ADMINISTRATION; UNITED STATES; VASOMOTOR REFLEX;

EID: 0031827653     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199807000-00002     Document Type: Review

References (101)

1. Kannel WB, Vokonas PS: Menopause and the risk of cardiovascular disease: the Framingham Study. Ann Intern Med 1976, 85:447-452.
2. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernester V, Cummings SR: Hormone replacement therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992, 117:1016-1037.
3. Natchigall LE, Natchigall RH, Natchigall RD, Beckman EM: Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979, 54:74-79.
4. Hasseger C, Riis BJ, Strom V, Guyene TT. Christiansen C: The long-term effect of oral and percutaneous estradiol on plasma renin substrate and blood pressure. Circulation 1987, 76:753-758.
5. Mercuro G, Zoncu S, Pilia I, Lao A, Melis GB, Cherchi A: Effects of acute administration of transdermal estrogen on postmenopausal women with systemic hypertension. Am J Cardiol 1997, 80:652-655. This is one of the first studies in which estrogen is shown to have a significant beneficial effect on mild to moderate hypertension.
6. The Writing Group from the PEPI trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995, 273:199-208.
7. Lobo RA: Estrogen and the Risk of coagulopathy. Am J Med 1992, 92:283-285.
8. Schunkert H, Danser AHJ, Hense H, Derkx FHM, Kürzinger S, Riegger GAJ: Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 1997, 95:39-45.
9. Clauser E, Gailard I, Wei L, Corvol P: Regulation of angiotensinogen gene. Am J Hypertens 1989, 2:403-410.
10. Feldmer M, Kalling M, Takahashi S, Mullins JJ, Ganten D: Glucocorticoid-and estrogen-responsive elements in the 5′-flanking region of the rat angiotensinogen gene. J Hypertens 1991, 9:1005-1012.
11. Lloyd T, Weisz J: Direct inhibition of tyrosine hydroxylase activity by estrogen. J Biol Chem 1987, 253:4841-4843.
12. Pasqualini C, Leviel V, Guibert B, Faucon-Biguet N, Kerdelhui B: Inhibitory action of acute estradiol treatment on the activity and quantity of tyrosine hydroxylase in the median eminence of ovariectomized rats. J Neuroendocrinol 1991, 3:575-580.
13. Lindheim SR, Legro RS, Bernstein L, Stanczyck FZ, Vijod MA, Presser SC, Lobo RA: Behavioral stress responses in premenopausal and postmenopausal women and the effects of estrogen. Am J Ostet Gynecol 1992, 167:183-1836.
14. Rio GD, Velardo A, Zizzo G, Avogaro A, Cipolli C, Casa LD, Marrama P, Macdonald IA: Effect of stress on the sympathoadrenal response to mental stress in normal men. J Clin Endocrinol 1994, 79:836-840.
15. Kasdorf G, Kalkhoff RK: Prospective studies of Insulin Sensitivity in Normal Women Receiving Oral Contraceptive Agents. J Clin Endocrinol Metab 1988, 66:846-852.
16. Laakso M: How good a marker is insulin level for insulin resistance? Am J Epidemiol 1993, 137:959-965.
17. Andersson B, Mattsson L, Hahn L, Marin P, Lapidus L, Holm G, Bengtsson B, Björntorp P: Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997, 82:638-643. This is one of the first studies to evaluate the effect of ERT on postmenopausal women with noninsulin dependent diabetes (a group known to be at increased risk of CAD).
18. Kannel WB: Metabolic risk factors for coronary heart disease in women: Perspective from the Framingham Study. Am Heart J 1987, 114:413-419.
19. Kim CJ, Min YK: Apoprotein(a)-lowering effect of hormone replacement therapy in postmenopausal women may be one mechanism of cardioprotective effect of estrogen [abstract]. J Am Coll Cardiol February (Special issue) 1994,431.
20. Bass KM, Newschaffer CJ, Klag MJ, Bush TL: Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993, 153:2209-2216.
21. Applebaum DM, Goldberg AP, Pykalisto OJ, et al.: Effect of estrogen on post-heprin lipolytic activity; selective decline in hepatic triglyceride lipase. J Clin Invest 1977, 59:601-608.
22. Wagner JD: "Effect of estrogens on arterial LDL metabolism." Presented at the AHA Scientific Conference on Hormonal Metabolism and Cellular influence on Cardiovascular Disease in Women. San Diego, CA, 1995.
23. Windler EE, Kovanen PR, Chao YS, Brown MS, Havel RJ, Goldstein JL: The estradiol-stimulated lipoprotein receptor of rat liver: a binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E. J Biol Chem 1980, 255:10464-10471.
24. Kovanen, PT, Brown MS, Goldstein JL: Increased binding of low-density lipoprotein to liver membrane from rats treated with 17 alpha-ethinyl estradiol. J Biol Chem 1979, 254:11376-11373.
25. Miller VT, La Rosa JC: Sex steroids and lipoproteins. In Lipids and Women's Health. Edited by Redmond GP. New York: Springer-Verlag. 1990:48.
26. Belchez PE: Hormonal treatment of postmenopausal women. N Engl J Med 1994, 330:1062-1071.
27. Lane G, Siddle MC, Ryder TA, Pryse-Davies J, King RJB, Whitehead MI: Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium. Br Med J 1983, 287:1241-1245.
28. Mautner SL, Lin F, Mautner GC, Roberts WC: Comparison in women versus men of composition of atherosclerotic plaques in native coronary arteries and in saphenous veins used as aortocoronary conduits. J Am Coll Cardiol 1993, 21:1312-1318.
29. Haarbo J, Leth-Espensen P, Stender S, Christiansen C: Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. J Clin Invest 1991, 87:1274-1279.
30. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB: Inhibition of coronary atherosclerosis by 17-betaestradiol in ovarioectomized monkeys. Arteriosclerosis 1990, 10:1051-1057.
31. Pick R, Stamler J, Rodbard S, Katz LN: The inhibition of coronary atherosclerosis by estrogens in cholesterol-fed chicks. Circulation 1952, 6:276-280.
32. Wagner JD, Clarkson TB, St. Clair RW, Schwenke DC, Shively CA. Adams MR: Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomologous monkeys. J Clin Invest 1990, 88:1995.
33. Hanke H, Hanke S, Finkling G, Muhic-Lohrer A, Muck AO, Schmahl FW, Haasis R, Hombach V: Different effects of estrogen and progesterone on experimental atherosclerosis in female versus male rabbits: quantification of cellular proliferation by bromodeoxyuridine. Circulation 1996, 94:175-181.
34. Stampfer MJ, Colditz GA: Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991, 20:47-59.
35. Nablusi AA, Folsom AR, Szklo M, White A, Higgins M, Heiss G. for the Atherosclerosis Risk in Communities (ARIC) Study Investigators: No association of menopause and hormone replacement therapy with carotied artery intima-media thickness. Circulation 1996, 94:1857-1863.
36. Manolio TA, Furberg C, Shemanski L, Psaty BM, O'Leary DH, Tracy RP. Bush TL: Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. Circulation 1993, 88:2163-2171.
37. Brown MS, Golstein JL: Scavenging for receptors. Nature 1990, 343:508-509.
38. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, et al.: Atherosclerosis: basic mechanisms-oxidation, inflammation, and genetics. Circulation 1995, 2488-2496.
39. Mukai K, Daifuku K, Yokoyama S, Nakano M: Stopped-flow investigation of antioxidant activity of estrogens in solution. Biochim Biophys Acta 1990, 1035:348-352.
40. Sugioka K, Shimosegawa Y, Nakano M: Estrogens as natural antioxidants of membrane phospholipid peroxidation. FEBS Lett 1987, 210:37-39.
41. Huber LA, Scheffler E, Poll T, Ziegler R, Dresel HA: 17β-estradiol inhibits LDL oxidation and cholesterol ester formation in cultured macrophages. Free Radic Res Commun 1990, 8:167-173.
42. Rifici VA and Khachadurian AK: The inhibition of low-density lipoprotein oxidation by 17β-estradiol. Metabolism 1992, 41:1110-1114.
43. Subbiah MTR, Kessel B, Agrawal M, Rajan R, Abplanalp W, Rymaszewski Z: Antioxidant potential of specific estrogens on lipid peroxidation. J Clin Endocinol Metab 1993, 77:1095-1097.
44. Sack MN, Rader DJ, Cannon RO: Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994, 343:269-270.
45. Guetta V, Panza JA, Waclawiw MA, Cannon RO: Effect of combined 17β-estradiol and vitamin E on low-density lipoprotein oxidation in postmenopausal women. Am J Cardiol 1995, 75:1274-1276.
46. Wagner JD, St. Clair RW, Schwencke DC, Shively CA, Adams MR, Clarkson TB: Regional differences in arterial low density lipoprotein metabolism in surgically postmenopausal cynomologus monkeys. Arterioscler Thromb
47. Yeung AC: Estrogen for men: reversal of cardiovascular misfortune? J Am Coll Cardiol 1997, 1445-1446.
48. Sacks FM, Walsh BW: The effects of reproductive hormones on serum lipoproteins: unresolved issues in biology and clinical practice. Ann N Y Acad Sci 1990, 592:272-285.
49. Jacobsson J, Cheng L, Lyke K, Kuwahara M, Kagan E, Ramwell PW, Foegh ML: Effect of estradiol on accelerated atherosclerosis in rabbit heterotopic aortic allografts. J Heart Lung Transplant 1992, 11:1188-1193.
50. Fischer GM, Cherian K, Swain ML: Increased synthesis of aortic collagen and elastin in experimental atherosclerosis: inhibition by contraceptive steroids. Atherosclerosis 1981, 39:463-467.
51. Fischer GM, Swain ML: Effect of sex hormones on blood pressure and vascular connective tissue in castrated and noncastrated male rats. Am J Physiol 1977, 232:6:H617-H621.
52. Bhalla RC, Toth KF, Bhatty RA, Thompson LP, Sharma RV: Estrogen reduces proliferation and agonist-induced calcium increase in coronary artery smooth muscle cells. Am J Physiol 1997, 272;H1996-H2003.
53. Taddei S, Virdis A, Ghiadoni L, Mattei P, Sudano I, Bernini G, Pinto S, Salvetti A: Menopause is associated with endothelial dysfunction in women Hypertension 1996, 28:576-582.
54. Pinto S, Virdis A, Ghiadoni L, Gianpolo B, Lombardo M, Petraglia F, Gonazzan AR, Taddei S, Salvetti A: Endogenous estrogen and acetylcholine-induced vasodilation in normotensive women. Hypertension 1997, 29(part 2):268-273.
55. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander W, Ganz P: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986, 315:1046-1051.
56. Gilligan DM, Quyyumi AA, Cannon RO: Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994, 89:2545-2551.
57. Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zacur HA, Gerstenblith G, Brinker JA: Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994, 89:52-60.
58. Collins P, Rosano GMC, Sarrel PM, Ulrich L, Adamopoulos S, Beale CM, McNeill JG, Poole-Wilson PA: 17β-estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995, 92:24-30.
59. Williams JK, Adams MR, Herrington DM, Clarkson TB: Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol 1992, 20:452-457.
60. Herrington DM, Braden GA, Williams JK, Morgan TM: Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol 1994, 73:951-952.
61. Reis SE, Bhoopalam V, Zell KA, Counihan PJ, Smith AJC, Pham S, Murali S: Conjugated estrogens acutely abolish abnormal cold-induced coronary vasoconstriction in male cardiac allografts. Circulation 1998, 97:23-25. This is the first study to evaluate the effects of estrogen on the coronary arteries of transplanted hearts in vivo.
62. McCrohon JA, Walters WAW, Robinson JTC, McCredie RJ, Turner L, Adams MR, Handelsman DJ, Celermajer DS: Arterial reactivity is enhanced in genetic males taking high dose estrogens. J Am Coll Cardiol 1997, 29:1432-1436. This study is instructive because it shows that estrogen may have a beneficial effect in genetic males.
63. New G, Timmins KL, Duffy SJ, Tran BT, O'Brien RC, Harper RW, Meredith IT: Long-term estrogen therapy improves vascular function in male to female transsexuals. J Am Coll Cardiol 1997, 29:1437-1444.
64. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, Ganz P, Creager MA, Yeaung AC, Selwyn AP: Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995, 26:1235-1241.
65. Herman SM, Robinson JC, McCradie RJ, Robinson JTC, Boyer MJ, Celermajer DS: Androgen deprivation is associated with improved endothelium-dependent dilation in adult men [abstract]. Circulation 1996, (suppl 1):1-278.
66. Collins P, Beale CM, Rosano GMC: Oestrogen as a calcium channel blocker, Eur Heart J 1996, 17(suppl D):27-31.
67. Jiang C, Poole-Wilson PA, Sarrel PM, Mochizuki S, Collins P, MacLeod KT: Effect of 17β-oestradiol in vitro. Br J Pharmacol 1991, 104:1033-1037.
68. Jiang C, Sarrel PM, Poole-Wilson PA, Collins P: Acute effect of 17β-estradiol on rabbit coronary artery contractile responses to endothelin-1. Am J Physiol 1992, 263;H271-H275.
69. Meyer MC, Cummings K, Osol G: Estrogen replacement attenuates resistance artery adrenergic sensitivity via endothelial vasodilators. Am J Phyiol 1997, 272:H2264-H2270. This study is important because it shows that ERT also has a beneficial effect on resistance-sized vessels, and it details the mechanisms by which ERT may effect this benefit.
70. Miller VM, Vanhoutte PM, 17β-Estradiol augments endothelium-dependent contractions to arachadonic acid in rabbit aorta. Am J Physiol 1990, 258:R1502-R1507.
71. Hayashi T, Fukuto JM, Ignarro LJ, Chaudhuri G: Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci USA 1994, 91:5212.
72. Roqué M, Heras M, Roig E, Rigol M, Massoti M, Betriu A, Serra A, Sanz G: Acute vascular effects of transdermal estrogen replacement therapy on coronary vascular reactivity in post-menopausal women [abstract] Circulation 1996, 1(suppl):1-279.
73. Best PJM, Berger PB, Miller VM, Lerman A: The effect of estrogen replacement therapy on plasma nitric oxide and endothelium-1 levels in postmenopausal women, Ann Intern Med 1998, 128:285-288.
74. Weiner CP, Lizasoain I, Bayleis SA, Knowless RG, Charles IG, Moncada S: Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA 1994, 91:5212.
75. Conrad KP, Joffe GM, Kruszna H, Rochelle LG, Smith RP, Chavez JE, Msosher MD: Identification of increased nitric oxide biosynthesis during pregnancy in rats. FASEB J 1993, 7:566-571.
76. Chang WC, Nakano J Orimo H, Murota SI: Stimulation of prostaglandin cyclooxygenase and prostacyclin synthase activities by estradiol in rat aortic smooth muscle cells. Biochim Biophys Acta 1980, 620:472.
77. Daly E, Vessey MP, Hawkins MM, Carson JL, Hough P, Marsh S: Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996, 348:977-980.
78. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM: Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996, 348:981-983.
79. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH: Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996, 348:983-987.
80. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB: Fibrinogen and risk of cardiovascular disease-The Framingham Study. JAMA 1987, 258:1183-1186.
81. Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, Waclawiw M, Cannon RO: Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997, 336:683-690. This study shows the degree to which ERT decreases PAI-1 in most women and that transdermal and oral estrogens have different effects on the fibrinolytic system.
82. Gebara OCE, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Welly FK, Wilson PWF, Levy D, Muller JE, Tofler GH: Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995, 91:1952-1958.
83. Shahar E, Folsom AR, Salomaa VV, Stinson VL, McGovern PG, Shimakawa T, Chambless LE, Wu KK, for the Atherosclerosis Risk in Communities (ARIC) Study Investigators: Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Circulation 1996, 93:1970-1975.
84. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ: Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick park heart study. Lancet 1993, 342:1076-1079.
85. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennedens CH: Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993, 34:1165-1168.
86. Olofsson BO, Dahlen G, Nilsson TK: Evidence for increased levels of plasminogen inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1989, 10:1077-1082.
87. Juhan-Vague I, Rijken DC, de Cock F, Mendez C, Collen D: Extrinsic plus minogen activator levels in clinical plasma samples. Prog Fibrinol 1983, 6:65-69.
88. Nablusi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Syzklo M for the Atherosclerosis Risk in Communities Study Investigators: Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993, 328:1069-75.
89. Lowe GDO, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA, Tunstall-Pedoe H: Epidemiology of coagulation factors, inhibitors and activation markers: the third Glasgow MONICA Survey I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997, 97:775-784.
90. Meade TW, Dyer S, Howarth DJ, Imeson JD, Stirling Y: Antithrombin III and procoagulant activity: sex differences and effects of the menopause. Br J Haematol 1990, 74:77-81.
91. Saleh AA, Dorey LG, Dombrowski MP, ginsburg KA, Hirokawa S, Kowalczyk C, Hirata J, Bottoms S, Cotton DB, Mammen EF: Thrombosis and hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol: 1993, 169:1554-1557.
92. Bush TL: Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy. Eur Heart J 1996, 17(suppl D):9-14.
93. Sullivan JM, Vander Zwaag R, Lemp GF, et al.: Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med 1988, 108:358-363.
94. Forrester JS, Merz CNB, Bush TL, et al.: Task force 4: efficacy of risk factor management. J Am Coll Cardiol 1996, 27:991-1006.
95. Rosano GMC, Sarrel PM, Poole-Wilson PA, Collins P: Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 1993, 342:133-136.
96. Holdright DR, Sullivan AK, Wright CA, Sparrow JL, Cunningham K, Fox KM: Acute effect of oestrogen replacement therapy on treadmill performance in postmenopausal women with coronary artery disease. Eur Heart J 1995, 16:1566-1570.
97. Sbarouni E, Kyriakides ZS, Nikolaou M, Kremastinos DT: Estrogen replacement therapy in postmenopausal women with coronary artery disease. Am J Cardiol 1997, 79:87-89.
98. Kranski K, Spyridopoloos I, Asahara T, Vanderzee R, Isner JM, Losordo DW: Estradiol accelerates functional endothelial recovery after arterial injury. Circulation 1997, 95:1768-1772.
99. O'Keefe JH, Kim SC, Hall RR, Cochran VC, Lawhorn SL, McCallister BD. Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol 1997, 29:1-5.
100. O'Brien JE, Peterson ED, Keeler GP, Berdan LG, Ohman EM, Faxon DP, Jacobs AK, Topol EJ: Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. J Am Coll Cardiol 1996, 28:1111-1118.
101. Sullivan JM, El-Zeky F, Vander Zwaag R, Ramanthan KB: Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am J Cardiol 1997, 79:847-850.